Authors
    • Medical Oncology
    Clinical Director of the Breast Oncology Program & Stuart B. Padnos Professor of Breast Cancer Research at University of Michigan Comprehensive Cancer Center
    Clinical Director of the Breast Oncology Program & Stuart B. Padnos Professor of Breast Cancer Research at University of...
    • Clinical Director of the Breast Oncology Program & Stuart B. Padnos Professor of Breast Cancer Research at University of Michigan Comprehensive Cancer Center

    Daniel F. Hayes, MD, FASCO, FACP Dr. Daniel F. Hayes is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, where he is the Stuart B. Padnos Professor of Breast Cancer Research. Dr. Hayes received bachelor’s, master’s and medical degrees from Indiana University, and completed aresidency in internal medicine at the University of Texas Health Science Center/Parkland Memorial Hospital and a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI). He has been  on faculty and led breast cancer programs at DFCI (1985-1996), Georgetown University’s Lombardi Cancer Center (1996 to 2001), and the University of Michigan (2001-present). Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers related to breast cancer, and particularly development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and tumor DNA. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility. Currently, he is chair of the SWOG Breast Cancer Translational Medicine Committee, and he is past chair of the Correlative Sciences Committee of the North American Breast Cancer Group. He was an inaugural member of the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee, which he co-chaired for the last decade. Dr. Hayes served on the 2011 to 2014 American Society of Clinical Oncology (ASCO) Board of Directors, and in has served as President of ASCO (2015-2018).  He is a Fellow of ASCO, a Komen Scholar, a member of the Association of American Physicians and of the American Clinical and Climatologic Association and of the Association of American Physicians, and he was the inaugural recipient of the ASCO Gianni Bonadonna Award. Dr. Hayes lives in Ann Arbor, Michigan, with his wife, Jane.

    • Medical Oncology
    • Professor Emerita in the Division of Medical Oncology and Department of Medicine, Medical Oncologist & Senior Scientist at the University of Toronto, Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre & Sunnybrook Research Institute, respectively

    Dr. Kathleen I. Pritchard, MD, FRCP(C) Dr. Kathleen I. Pritchard is a Professor Emerita in the Division of Medical Oncology and Department of Medicine at the University of Toronto, a Medical Oncologist at the Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre and a Senior Scientist at the Sunnybrook Research Institute (all in Toronto, Ontario, Canada). Dr. Pritchard’s research interests are focused in breast cancer and include the conduct of large clinical trials, meta-analysis, adjuvant therapy, endocrine therapy and correlative and translational research in breast cancer. She has published over 300 peer reviewed publications and is one of the Top 1% Highly Cited Researchers in Clinical Medicine by Thomson Reuters (2014-Present). A graduate of Queens University’s School of Medicine in 1971, Dr Pritchard trained in medicine and medical oncology in the University of Toronto system from 1971 through 1978 and has been a faculty member of the University of Toronto (1978-Present), appointed first at Women’s College Hospital (WCH) (1978-1987) and subsequently at Sunnybrook Health Sciences Centre (1987-Present). She was Head of the Division of Medical Oncology at WCH from 1984 to 1987 and of the Division of Medical Oncology and Hematology of Sunnybrook Health Sciences Centre from 1987 to 1999 and Head of Clinical Trials and Epidemiology at Sunnybrook Health Sciences Centre from 1998 to 2008. She was Departmental Division Director of the Division of Medical Oncology, Department of Medicine, University of Toronto from 2011 to 2017. She was Chair/Co-Chair of the Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) (now Canadian Cancer Trials Group (CCTG)) (1984-2007) and Past Chair (2007-Present). Dr. Pritchard served as Chair of the Management Committee of the Canadian Breast Cancer Research Initiative (Alliance) (1999-2002), as a member of the Board of Directors of the Canadian Breast Cancer Foundation (CBCF), Ontario Division (2010-2015) and of the American Society of Clinical Oncology (ASCO) Board of Directors (2007-2010). She has served on the Editorial Boards of the Annals of Internal Medicine (1986-1989) and the Journal of Clinical Oncology (2002-2005, 2010-2016) and the European Journal of Cancer and the Oncologist (2010-2016). She is currently a Co-Associate Editor of the Oncologist. Dr. Pritchard has been awarded the Sunnybrook Department of Medicine Research Award (1996), Sunnybrook Women’s Health Research Award (2004-2005) and the first Division of Medical Oncology Research Award from the University of Toronto (2008). Dr. Pritchard was awarded the O. Harold Warwick Prize for Cancer Control in Canada in 2005 by the Canadian Cancer Society (CCS) and was named the Cosbie Lecturer by CCS and Cancer Care Ontario in 2008. In June 2011, Dr. Pritchard was awarded the ASCO Statesman Award. In 2015, Dr. Pritchard was awarded a Lifetime Achievement Award by the Canadian Breast Cancer Foundation (CBCF) and named a Woman of Action by the Israel Cancer Research Foundation (ICRF). In 2016 she was awarded the Founder’s Award: Dr. Joseph Pater Excellence in Clinical Trials Research Award by the Canadian Cancer Trials Group (CCTG).

Want to stay updated? Follow Discussion & Ask Your Question